13F Pro13F Pro

ARMISTICE CAPITAL, LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1601086
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare67.9%$2.5B
  • Technology18.6%$673.0M
  • Consumer Discretionary7.1%$255.3M
  • Consumer Staples3.3%$120.7M
  • Communication Services1.2%$43.1M
  • Industrials0.9%$31.2M
  • Other0.4%$12.9M
  • Materials0.2%$8.8M
  • Financials0.2%$5.7M
  • Energy0.1%$3.8M

AUM History

13fpro.ai/research/fund/armistice-capital-llc-1601086

Conviction and streaks

Diversifying · top 10 = 27.4%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

MDGL$MDGLConviction hold4.3% weight · held 10 quartersSUPN$SUPNConviction hold3.4% weight · held 10 quartersCYTK$CYTKConviction hold2.8% weight · held 10 quartersINCY$INCYConviction hold2.8% weight · held 10 quartersNBIX$NBIXConviction hold2.5% weight · held 10 quartersARAY$ARAYAccumulating+1047% shares · 7 quarters runningLEN$LENAccumulating+1005% shares · 6 quarters runningTMO$TMOAccumulating+511% shares · 5 quarters runningHUBS$HUBSAccumulating+1379% shares · 5 quarters runningMLYS$MLYSAccumulating+875% shares · 4 quarters runningPTCT$PTCTTrimming-85% shares · 7 quarters runningVYGR$VYGRTrimming-37% shares · 5 quarters runningIMVT$IMVTTrimming-70% shares · 3 quarters runningIRWD$IRWDTrimming-14% shares · 3 quarters runningANRO$ANROTrimming-47% shares · 3 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/armistice-capital-llc-1601086

ARMISTICE CAPITAL, LLC 13F holdings — Q2 2026

$8.2B portfolio (+45.3% QoQ) · 333 holdings · Q2 2026 13F · top 10 are 27% of the stock portfolio

Includes $4.6B of put/call options ($4.1B puts, $426.6M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $3.6B. Weights use the stock portfolio.

All holdings — ARMISTICE CAPITAL, LLC (Q2 2026)

333 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
SPY$SPYPUTSPDR S&P 500 ETF TRUST$2.4B+52%
— PUTISHARES TR - RUSSELL 2000 ETF$1.7B+66%
CYTK$CYTKCALLCYTOKINETICS INC$130.3M-10%
AGIO$AGIOCALLAGIOS PHARMACEUTICALS, INC.$104.3M-12%
DYN$DYNDyne Therapeutics, Inc.$68.6M-3%
AMZN$AMZNAMAZON COM INC$67.8M+9%
IMVT$IMVTImmunovant, Inc.$66.9M-51%
RIGL$RIGLRIGEL PHARMACEUTICALS INC$65.4M+31%
TMO$TMOTHERMO FISHER SCIENTIFIC INC.$61.4M+34%
IRWD$IRWDIRONWOOD PHARMACEUTICALS INC$58.7M-7%
HRMY$HRMYHarmony Biosciences Holdings, Inc.$56.9M-4%
REGN$REGNREGENERON PHARMACEUTICALS, INC.$56.0M+149%
PTCT$PTCTCALLPTC THERAPEUTICS, INC.$53.8M+69%
NKTR$NKTRNEKTAR THERAPEUTICS$50.5M+25%
MLYS$MLYSMineralys Therapeutics, Inc.$46.8M+48%

What changed in Q2 2026

Against the previous quarter's 13F: 170 new, 73 added to, 69 trimmed, 99 sold out. Share-count changes; largest moves by dollar size first.

New positions (170)

  • TVTX$TVTXCALLTravere Therapeutics, Inc.$28.4M

    first bought this quarter

  • WAT$WATWATERS CORP /DE/$28.1M

    first bought this quarter

  • MLYS$MLYSCALLMineralys Therapeutics, Inc.$28.1M

    first bought this quarter

  • ILMN$ILMNILLUMINA, INC.$16.0M

    first bought this quarter

  • PBH$PBHPrestige Consumer Healthcare Inc.$15.9M

    first bought this quarter

  • FWONA$FWONALiberty Media Corp$15.7M

    first bought this quarter

+164 more in the Excel export

Added to (73)

  • SPY$SPYPUTSPDR S&P 500 ETF TRUST+52%

    now $2.4B

  • PUTISHARES TR - RUSSELL 2000 ETF+66%

    now $1.7B

  • CYTK$CYTKCYTOKINETICS INC+57%

    now $102.3M · held 10+ qtrs

  • SUPN$SUPNSUPERNUS PHARMACEUTICALS, INC.+40%

    now $123.1M · held 10+ qtrs

  • REGN$REGNREGENERON PHARMACEUTICALS, INC.+149%

    now $56.0M · held 10+ qtrs

  • SNY$SNYSanofi+255%

    now $45.4M · held 4 qtrs

+67 more in the Excel export

Trimmed (69)

  • TVTX$TVTXTravere Therapeutics, Inc.-68%

    now $89.3M · held 10+ qtrs

  • PTCT$PTCTPTC THERAPEUTICS, INC.-48%

    now $87.4M · held 10+ qtrs, 7 trims in a row

  • IMVT$IMVTImmunovant, Inc.-51%

    now $66.9M · held 10+ qtrs, 3 trims in a row

  • DDOG$DDOGDatadog, Inc.-82%

    now $9.8M · held 10+ qtrs, 2 trims in a row

  • NBIX$NBIXNEUROCRINE BIOSCIENCES INC-26%

    now $90.3M · held 10+ qtrs, 2 trims in a row

  • HUM$HUMHUMANA INC-49%

    now $28.8M · held 4 qtrs

+63 more in the Excel export

Sold out (99)

  • AVNS$AVNSAVANOS MEDICAL, INC.was $28.0M

    held 5 qtrs

  • MDLN$MDLNMedline Inc.was $25.1M

    held 2 qtrs

  • KALV$KALVKalVista Pharmaceuticals, Inc.was $24.9M

    held 2 qtrs

  • ENR$ENRENERGIZER HOLDINGS, INC.was $19.7M

    held 2 qtrs

  • FIVN$FIVNCALLFive9, Inc.was $19.0M
  • META$METAMeta Platforms, Inc.was $18.6M

    held 1 qtr

+93 more in the Excel export

Firm AUM (Form ADV): $4.7B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F ARMISTICE CAPITAL, LLC has filed, 39 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow ARMISTICE CAPITAL?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of ARMISTICE CAPITAL's top 20 holdings: 53/100 (our AI quality score, weighted by position size; 17 of the 20 are scored)

Top 10 since filing

-9.8%

Value-weighted move of the 10 largest stock positions

Turnover

26%

Last quarter; 85% over the last 4

Top 10 weight

27%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

79%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

ARMISTICE CAPITAL, LLC disclosed 333 positions worth $8.2B in its Form 13F-HR for Q2 2026 — $3.6B in common stock plus $4.6B of put/call option positions (reported at underlying notional value, not premium at risk), led by $MDGL (MADRIGAL PHARMACEUTICALS, INC.) at 4.3% of the equity portfolio, followed by $SUPN and $CYTK. During the quarter the fund opened 170 new positions and exited 99 — including a new stake in $TVTX and a full exit from $AVNS. The portfolio is most concentrated in Healthcare (67.9% of disclosed assets). All figures are sourced directly from ARMISTICE CAPITAL, LLC’s Form 13F-HR filing with the SEC under CIK 1601086.

Funds like this

managers whose biggest positions overlap ARMISTICE CAPITAL's
RTW INVESTMENTS, LP$11.71B 13F book · 6 shared top holdingsMDGLPTCTCYTKNBIXVestal Point Capital, LP$4.28B 13F book · 8 shared top holdingsNBIXDYNNKTRSNYBAKER BROS. ADVISORS LP$19.96B 13F book · 3 shared top holdingsMDGLINCYIMVTRock Springs Capital Management LP$2.05B 13F book · 6 shared top holdingsMDGLTVTXNBIXDYNIntegral Health Asset Management, LLC$2.53B 13F book · 4 shared top holdingsCYTKNBIXREGNTVTXADAR1 Capital Management, LLC$2.19B 13F book · 5 shared top holdingsIMVTAGIOCYTKNKTR

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: ARMISTICE CAPITAL, LLC

13F Pro is an AI hedge fund tracker and stock research platform. For ARMISTICE CAPITAL, LLC (SEC CIK: 1601086), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in ARMISTICE CAPITAL, LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.